Skip to main content

Table 2 Lipid parameters before and after administration of dapagliflozin or sitagliptin

From: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

 

Dapagliflozin (n = 40)

Sitagliptin (n = 40)

p valueb

Pre treatment

Post treatment

% change

p valuea

Pre treatment

Post treatment

% change

p valuea

Total-C (mg/dL)

193.5 ± 36.6

198.4 ± 45.9

2.5

0.863

192.5 ± 58.2

195.5 ± 38.9

1.6

0.720

0.102

TG (mg/dL)

152.6 ± 63.7

133.7 ± 75.8

−12.4

0.145

150.2 ± 85.2

144.6 ± 87.2

−3.7

0.245

0.928

HDL-C (mg/dL)

48.4 ± 11.1

53.5 ± 13.0

10.5

<0.001*

50.3 ± 9.25

50.3 ± 11.1

0

0.948

0.003*

LDL-C (mg/dL)

118.2 ± 32.1

118.8 ± 39.7

0.5

0.875

120.2 ± 35.1

114.7 ± 33.1

−4.6

0.257

0.323

Non HDL-C (mg/dL)

145.1 ± 36.0

144.9 ± 439

−0.1

0.947

142.2 ± 57.3

145.1 ± 38.4

2.9

0.717

0.328

Apo AI (mg/dL)

133.5 ± 21.6

143.5 ± 22.6

7.5

0.002*

134.9 ± 25.2

128.8 ± 30.7

−4.5

0.135

0.002*

Apo AII (mg/dL)

29.7 ± 4.5

30.9 ± 5.0

4.0

0.022*

30.5 ± 7.2

30.5 ± 7.2

0

0.945

0.148

Apo B (mg/dL)

100.1 ± 24.5

100.8 ± 28.1

0.7

0.777

102.3 ± 27.7

97.4 ± 26.5

−4.8

0.123

0.131

Apo CII (mg/dL)

4.8 ± 1.7

4.9 ± 2.2

2.1

0.362

5.4 ± 2.8

5.1 ± 2.6

−5.6

0.197

0.105

Apo CIII (mg/dL)

10.5 ± 3.2

11.4 ± 4.3

8.6

0.021*

10.1 ± 4.5

9.6 ± 4.0

−5.0

0.335

0.028*

Apo E (mg/dL)

4.4 ± 1.2

4.4 ± 1.5

0

0.530

4.3 ± 1.5

4.1 ± 1.0

−4.7

0.296

0.216

RLP-C (mg/dL)

6.8 ± 4.3

6.4 ± 5.1

−5.9

0.620

6.9 ± 8.0

6.1 ± 5.7

−11.6

0.303

0.750

HDL2-C (mg/dL)

26.1 ± 8.2

30.8 ± 10.8

18.0

<0.001*

26.6 ± 7.9

27.5 ± 8.4

3.4

0.334

0.013*

HDL3-C (mg/dL)

22.2 ± 3.9

22.7 ± 5.0

2.3

0.527

23.3 ± 5.2

22.2 ± 5.3

−4.7

0.132

0.130

sd LDL-C (mg/dL)

54.4 ± 24.6

43.6 ± 24.4

−19.9

0.005*

54.0 ± 22.5

50.4 ± 22.4

−6.7

0.368

0.003*

lb LDL-C (mg/dL)

63.8 ± 27.6

75.1 ± 34.1

17.7

0.026*

66.2 ± 26.3

64.3 ± 24.1

−2.9

0.671

0.029*

  1. Data are expressed as mean ± standard deviation or percent changes after the treatment
  2. Total-C total-cholesterol, TG triglycerides, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, Apo apolipoprotein, RLP-C remant-like particles-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 3-cholesterol
  3. ap values for the intragroup comparison (pre vs. post treatment values in dapagliflozin or sitagliptin group, * p < 0.05)
  4. bp values for intergroup comparison (dapagliflozin vs. sitagliptin group in the changes from pre to post treatment, * p < 0.05)
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840